10-K/A: Kineta Files Amendment to 10-K, Providing Additional Corporate Governance and Executive Compensation Details

Kineta, Inc. files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted information regarding directors, executive officers, corporate governance, and executive compensation.

Summary

• Kineta, Inc. is filing Amendment No. 1 on Form 10-K/A to its original Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
• The amendment includes information required by Part III of Form 10-K, which was previously omitted.
• The company is also filing new certifications from the principal executive officer and principal financial officer.
• The amendment updates the cover page to remove reference to the proxy statement and update the date for outstanding shares.
• The aggregate market value of voting and non-voting common equity held by non-affiliates as of June 30, 2024, was $2.5 million.
• As of April 25, 2025, there were 13,540,355 shares of common stock outstanding.

Sentiment

Score: 6

Explanation: The document is primarily factual and procedural, with a neutral tone. It provides necessary updates and disclosures, but does not contain information that would significantly sway investor sentiment positively or negatively.

Future Outlook

The document does not contain specific forward-looking statements beyond the pending merger with TuHURA Biosciences.

Industry Context

This filing is a routine update to comply with SEC regulations, providing transparency on corporate governance and executive compensation, which is standard practice in the biopharmaceutical industry.

Comparison to Industry Standards

• The executive compensation structure, including base salary, bonus, and equity awards, is typical for a biopharmaceutical company of Kineta's size and stage.
• The board composition and committee structure align with Nasdaq requirements for listed companies.
• The related party transaction policy is consistent with standard corporate governance practices to ensure transparency and prevent conflicts of interest.

Management Changes

Related Party Transactions

• In connection with the Yumanity Merger, we entered into a securities purchase agreement (the Securities Purchase Agreement) on June 5, 2022 and as amended on October 24, 2022, December 5, 2022, March 29, 2023, May 1, 2023, July 21, 2023 and October 13, 2023 with certain investors (the Purchasers) for the sale of shares of common stock to such Purchasers in a private placement (the Private Placement).

Stakeholder Impact

• Shareholders receive updated information on corporate governance and executive compensation.
• Employees are affected by the reduction in workforce plan.
• Directors and officers are subject to support and lock-up agreements related to the TuHURA merger.

Next Steps

• The company is seeking a strategic partnership.
• The company is working towards closing the TuHURA Merger.

Key Dates

Keywords

Form 10-K/A, amendment, executive compensation, corporate governance, directors, Kineta, financial reporting